Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures

被引:31
作者
Benzie, Andrew A.
Bansi, Loveleen K.
Sabin, Caroline A.
Portsmouth, Simon
Hill, Teresa
Johnson, Margaret
Gilson, Richard
Easterbrook, Philippa
Gazzard, Brian
Fisher, Martin
Orkin, Chloe
Dunn, David
Delpech, Valerie
Taylor, Graham P.
Walsh, John C.
Phillips, Andrew N.
机构
[1] St Marys Hosp, London, England
[2] UCL Royal Free & Univ Coll, Sch Med, London, England
[3] UCL Royal Free NHS Trust, London, England
[4] Guys Kings & St Thomas Sch Med, London, England
[5] Chelsea & Westminster Hosp, London, England
[6] Brighton & Sussex Univ Hosp Trust, Brighton, E Sussex, England
[7] Barts & London NHS Trust, London, England
[8] Brighton & Sussex Univ Hosp Trust, London, England
[9] Med Res Council Clin Trials Unit, London, England
基金
英国医学研究理事会;
关键词
HAART; viral suppression; viral rebound; long-term follow up; treatment failure;
D O I
10.1097/QAD.0b013e3281532ca7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: We investigated whether the rate of viral rebound decreases with increasing duration of viral suppression and, if so, whether rebound rates in patients previously failing antiretroviral regimens ultimately decline to levels as low as those seen in patients who have never experienced virological failure. Methods: All patients from the UK CHIC Study (n = 21256) who achieved a viral load (VL) of < 50copies/ml while receiving HAART were followed until viral rebound (two consecutive VL > 400copies/ml). Patients could re-enter the analysis if they experienced a subsequent VL < 50 copies/ml. Rebound rates were calculated according to the number of regimens previously failed and duration of viral suppression. Results: Of 12 648 patients on HAART 10237 (80.9%) achieved a VL <= 50copies/ml. During 26494 person-years (PY) of follow-up, 1853 (18.1%) patients experienced at least one viral rebound 'event', with 2460 events in total [rebound rate, 9.3 (range, 8.9-9.7)/100 PY). Within the first year of viral suppression, the rate of viral rebound was 8.3 (7.5-9.1)/100 PY in patients who had not previously failed treatment, increasing to 32.7 (27.6-37.8)/100 PY in patients who had failed more than four regimens. Irrespective of previous treatment failure, rebound rates in those who remained suppressed for > 4 years were similar to those in patients who had at no time experienced treatment failure. Conclusion: After around 4 years of viral suppression rebound rates in individuals with multiple prior treatment failures approach those of individuals with no prior treatment failure. (c) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1423 / 1430
页数:8
相关论文
共 21 条
[1]  
*COLL HIV COH, 2004, J INFECT DIS, V190, P1261
[2]   Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection [J].
Deeks, SG ;
Barbour, JD ;
Martin, JN ;
Swanson, MS ;
Grant, RM .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :946-953
[3]   Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].
Durant, J ;
Clevenbergh, P ;
Halfon, P ;
Delgiudice, P ;
Porsin, S ;
Simonet, P ;
Montagne, N ;
Boucher, CAB ;
Schapiro, JM ;
Dellamonica, P .
LANCET, 1999, 353 (9171) :2195-2199
[4]  
JOHNSON V, 2004, 11 C RETR OPP INF SA
[5]   Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine [J].
Kempf, DJ ;
King, MS ;
Bernstein, B ;
Cernohous, P ;
Bauer, E ;
Moseley, J ;
Gu, K ;
Hsu, A ;
Brun, S ;
Sun, E .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (01) :51-60
[6]  
LE MV, 2002, AIDS, V16, P21
[7]   Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes [J].
Ledergerber, B ;
Lundgren, JD ;
Walker, AS ;
Sabin, C ;
Justice, A ;
Reiss, P ;
Mussini, C ;
Wit, F ;
Monforte, AD ;
Weber, R ;
Fusco, G ;
Staszewski, S ;
Law, M ;
Hogg, R ;
Lampe, F ;
Gill, MJ ;
Castelli, F ;
Phillips, AN ;
Castelli, F ;
Fusco, GP ;
Gill, MJ ;
Hogg, R ;
Lampe, F ;
Law, M ;
Ledergerber, B ;
Lundgren, JD ;
Monforte, AD ;
Mussini, C ;
Phillips, AN ;
Reiss, P ;
Staszewski, S ;
Walker, AS ;
Rooney, P ;
Taylor, S ;
Couldwell, D ;
Austin, D ;
Block, M ;
Clemons, J ;
Finlayson, R ;
Law, M ;
Petoumenos, K ;
Quan, D ;
Smith, D ;
O'Connor, C ;
Gorton, C ;
Allen, D ;
Mulhall, B ;
Mutimer, K ;
Smith, D ;
Keeffe, N .
LANCET, 2004, 364 (9428) :51-62
[8]   Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study [J].
Ledergerber, B ;
Egger, M ;
Opravil, M ;
Telenti, A ;
Hirschel, B ;
Battegay, M ;
Vernazza, P ;
Sudre, P ;
Flepp, M ;
Furrer, H ;
Francioli, P ;
Weber, R .
LANCET, 1999, 353 (9156) :863-868
[9]   CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load [J].
Miller, V ;
Staszewski, S ;
Sabin, C ;
Carlebach, A ;
Rottmann, C ;
Weidmann, E ;
Rabenau, H ;
Hill, A ;
Lepri, AC ;
Phillips, AN .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :530-533
[10]   Virological rebound after suppression on highly active antiretroviral therapy [J].
Mocroft, A ;
Ruiz, L ;
Reiss, P ;
Ledergerber, B ;
Katlama, C ;
Lazzarin, A ;
Goebel, FD ;
Phillips, AN ;
Clotet, B ;
Lundgren, JD .
AIDS, 2003, 17 (12) :1741-1751